Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Conditions

Lymphoma 260Lymphoma, Non-Hodgkin 205Leukemia, Lymphocytic, Chronic, B-Cell 193Lymphoma, Large B-Cell, Diffuse 187Lymphoma, Follicular 168Lymphoma, Mantle-Cell 134Leukemia 81Lymphoma, B-Cell, Marginal Zone 80Burkitt Lymphoma 54Waldenstrom Macroglobulinemia 52Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Lymphoma, B-Cell 47Lymphoma, Large-Cell, Immunoblastic 42Hodgkin Disease 39Recurrence 35Lymphoma, Large-Cell, Anaplastic 18Multiple Myeloma 16Neoplasms 13Myelodysplastic Syndromes 12Hematologic Neoplasms 12Leukemia, Myeloid, Acute 11Lymphoma, T-Cell 9Intraocular Lymphoma 9Dendritic Cell Sarcoma, Interdigitating 9Leukemia, Prolymphocytic 7Neoplasms, Plasma Cell 6Leukemia, Hairy Cell 6Leukemia, B-Cell 6Graft vs Host Disease 6Arthritis, Rheumatoid 6

Interventions

Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Off-Label Use × Rituximab × Clear all
NCT02654379 2018-04-09

Observational Study Evaluating Rituximab Use and Use of the Patient Alert Card in Participants Receiving Rituximab Infusion for a Non-Oncology Indication at Infusion Centers in Europe

Hoffmann-La Roche

Completed
1,408 enrolled

Off-Label Use

Data powered by HemOnc (CC BY 4.0) Colophon âš¡